GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004211018 | Esophagus | ESCC | T cell activation | 256/8552 | 487/18723 | 1.18e-03 | 5.87e-03 | 256 |
GO:19031317 | Esophagus | ESCC | mononuclear cell differentiation | 226/8552 | 426/18723 | 1.20e-03 | 5.88e-03 | 226 |
GO:00025442 | Esophagus | ESCC | chronic inflammatory response | 15/8552 | 18/18723 | 1.20e-03 | 5.88e-03 | 15 |
GO:002240919 | Esophagus | ESCC | positive regulation of cell-cell adhesion | 155/8552 | 284/18723 | 1.50e-03 | 7.06e-03 | 155 |
GO:000223719 | Esophagus | ESCC | response to molecule of bacterial origin | 194/8552 | 363/18723 | 1.64e-03 | 7.61e-03 | 194 |
GO:0097305111 | Esophagus | ESCC | response to alcohol | 138/8552 | 253/18723 | 2.70e-03 | 1.14e-02 | 138 |
GO:005087015 | Esophagus | ESCC | positive regulation of T cell activation | 117/8552 | 216/18723 | 7.23e-03 | 2.62e-02 | 117 |
GO:190303916 | Esophagus | ESCC | positive regulation of leukocyte cell-cell adhesion | 128/8552 | 239/18723 | 8.40e-03 | 2.96e-02 | 128 |
GO:000715918 | Esophagus | ESCC | leukocyte cell-cell adhesion | 192/8552 | 371/18723 | 1.03e-02 | 3.51e-02 | 192 |
GO:00350512 | Esophagus | ESCC | cardiocyte differentiation | 86/8552 | 156/18723 | 1.09e-02 | 3.68e-02 | 86 |
GO:00341135 | Esophagus | ESCC | heterotypic cell-cell adhesion | 37/8552 | 61/18723 | 1.32e-02 | 4.31e-02 | 37 |
GO:190303717 | Esophagus | ESCC | regulation of leukocyte cell-cell adhesion | 174/8552 | 336/18723 | 1.36e-02 | 4.43e-02 | 174 |
GO:00300984 | Esophagus | ESCC | lymphocyte differentiation | 192/8552 | 374/18723 | 1.52e-02 | 4.93e-02 | 192 |
GO:007048219 | Oral cavity | OSCC | response to oxygen levels | 200/7305 | 347/18723 | 1.17e-12 | 5.13e-11 | 200 |
GO:007149620 | Oral cavity | OSCC | cellular response to external stimulus | 186/7305 | 320/18723 | 2.56e-12 | 1.05e-10 | 186 |
GO:00102128 | Oral cavity | OSCC | response to ionizing radiation | 99/7305 | 148/18723 | 5.49e-12 | 2.08e-10 | 99 |
GO:000756818 | Oral cavity | OSCC | aging | 194/7305 | 339/18723 | 6.18e-12 | 2.33e-10 | 194 |
GO:000166619 | Oral cavity | OSCC | response to hypoxia | 177/7305 | 307/18723 | 2.21e-11 | 7.50e-10 | 177 |
GO:003629319 | Oral cavity | OSCC | response to decreased oxygen levels | 182/7305 | 322/18723 | 1.14e-10 | 3.41e-09 | 182 |
GO:000931416 | Oral cavity | OSCC | response to radiation | 241/7305 | 456/18723 | 9.76e-10 | 2.40e-08 | 241 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05418211 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa05417211 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa0493310 | Esophagus | ESCC | AGE-RAGE signaling pathway in diabetic complications | 72/4205 | 100/8465 | 4.15e-06 | 2.28e-05 | 1.17e-05 | 72 |
hsa05418310 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
hsa0466817 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
hsa05417310 | Esophagus | ESCC | Lipid and atherosclerosis | 143/4205 | 215/8465 | 3.30e-07 | 2.45e-06 | 1.26e-06 | 143 |
hsa0493317 | Esophagus | ESCC | AGE-RAGE signaling pathway in diabetic complications | 72/4205 | 100/8465 | 4.15e-06 | 2.28e-05 | 1.17e-05 | 72 |
hsa046689 | Oral cavity | OSCC | TNF signaling pathway | 82/3704 | 114/8465 | 8.30e-10 | 9.59e-09 | 4.88e-09 | 82 |
hsa0541830 | Oral cavity | OSCC | Fluid shear stress and atherosclerosis | 92/3704 | 139/8465 | 6.51e-08 | 4.84e-07 | 2.47e-07 | 92 |
hsa049339 | Oral cavity | OSCC | AGE-RAGE signaling pathway in diabetic complications | 69/3704 | 100/8465 | 2.61e-07 | 1.65e-06 | 8.41e-07 | 69 |
hsa0467030 | Oral cavity | OSCC | Leukocyte transendothelial migration | 63/3704 | 114/8465 | 8.46e-03 | 1.96e-02 | 9.95e-03 | 63 |
hsa0466816 | Oral cavity | OSCC | TNF signaling pathway | 82/3704 | 114/8465 | 8.30e-10 | 9.59e-09 | 4.88e-09 | 82 |
hsa05418114 | Oral cavity | OSCC | Fluid shear stress and atherosclerosis | 92/3704 | 139/8465 | 6.51e-08 | 4.84e-07 | 2.47e-07 | 92 |
hsa0493316 | Oral cavity | OSCC | AGE-RAGE signaling pathway in diabetic complications | 69/3704 | 100/8465 | 2.61e-07 | 1.65e-06 | 8.41e-07 | 69 |
hsa04670113 | Oral cavity | OSCC | Leukocyte transendothelial migration | 63/3704 | 114/8465 | 8.46e-03 | 1.96e-02 | 9.95e-03 | 63 |
hsa0493361 | Oral cavity | NEOLP | AGE-RAGE signaling pathway in diabetic complications | 32/1112 | 100/8465 | 7.36e-07 | 9.10e-06 | 5.72e-06 | 32 |
hsa0541863 | Oral cavity | NEOLP | Fluid shear stress and atherosclerosis | 40/1112 | 139/8465 | 7.44e-07 | 9.10e-06 | 5.72e-06 | 40 |
hsa0467046 | Oral cavity | NEOLP | Leukocyte transendothelial migration | 31/1112 | 114/8465 | 4.39e-05 | 3.41e-04 | 2.14e-04 | 31 |
hsa0541763 | Oral cavity | NEOLP | Lipid and atherosclerosis | 47/1112 | 215/8465 | 2.39e-04 | 1.61e-03 | 1.01e-03 | 47 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
VCAM1 | SNV | Missense_Mutation | rs190280671 | c.1259N>G | p.Ser420Cys | p.S420C | P19320 | protein_coding | deleterious(0) | benign(0.379) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
VCAM1 | SNV | Missense_Mutation | novel | c.1157N>G | p.Thr386Ser | p.T386S | P19320 | protein_coding | tolerated(0.15) | benign(0.048) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
VCAM1 | SNV | Missense_Mutation | | c.1941N>T | p.Lys647Asn | p.K647N | P19320 | protein_coding | tolerated(0.19) | benign(0.049) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
VCAM1 | SNV | Missense_Mutation | | c.673N>T | p.Asn225Tyr | p.N225Y | P19320 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
VCAM1 | SNV | Missense_Mutation | novel | c.1170G>T | p.Lys390Asn | p.K390N | P19320 | protein_coding | tolerated(0.12) | possibly_damaging(0.685) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
VCAM1 | SNV | Missense_Mutation | rs200879051 | c.1967G>A | p.Arg656Gln | p.R656Q | P19320 | protein_coding | tolerated(0.14) | benign(0.011) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
VCAM1 | SNV | Missense_Mutation | novel | c.661N>C | p.Ile221Leu | p.I221L | P19320 | protein_coding | tolerated(0.13) | benign(0.042) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
VCAM1 | SNV | Missense_Mutation | | c.821C>A | p.Ala274Glu | p.A274E | P19320 | protein_coding | tolerated(0.45) | probably_damaging(0.991) | TCGA-B6-A1KC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
VCAM1 | SNV | Missense_Mutation | | c.1441C>T | p.Leu481Phe | p.L481F | P19320 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
VCAM1 | SNV | Missense_Mutation | novel | c.1019N>T | p.Cys340Phe | p.C340F | P19320 | protein_coding | tolerated(0.09) | probably_damaging(0.993) | TCGA-E2-A1LL-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | docetaxel | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7412 | VCAM1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | TROGLITAZONE | TROGLITAZONE | 10626906 |
7412 | VCAM1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | PMA | | 7678355 |
7412 | VCAM1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | PHORBOL MYRISTATE ACETATE | | 7678355 |
7412 | VCAM1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | AGI-1067, SUCCINOBUCOL | | |
7412 | VCAM1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | 6-MERCAPTOPURINE | MERCAPTOPURINE | 7694584 |
7412 | VCAM1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | DEXAMETHASONE | DEXAMETHASONE | 7694584 |
7412 | VCAM1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | CYCLOSPORINE | CYCLOSPORINE | 7694584 |